Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-01-25 @ 11:20 AM
Study NCT ID:
NCT02142192
Status:
TERMINATED
Last Update Posted:
2024-06-03
First Post:
2014-05-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Natalizumab Subcutaneous Immunogenicity and Safety Study
Sponsor:
Biogen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
101MS207
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None